When Bad Data Enters the Drug Pipeline - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

  • By

  • Kathryn Wighton

  • June 11, 2026

  • 2 min

Share

  • 1

    Jaynier Moya, MD, and three coordinators face charges for allegedly falsifying data in drug trials at Pines Care Research Center.

  • 2

    The alleged misconduct reportedly began no later than 2019, involving false records of participant medication and testing.

  • 3

    Prosecutors claim identification documents from non-participants were used to create fraudulent participant records.

  • 4

    Falsified data was allegedly submitted into clinical trial databases, impacting evaluations of new drugs.

  • 5

    The case highlights the importance of data integrity in clinical trials for regulatory evaluations and public confidence.

Original Source(s)

When Bad Data Enters the Drug Pipeline

  • by Kathryn Wighton

  • June 11, 2026

Related Content

Can Endotoxin-Targeted Care Improve Sepsis Outcomes?

Biomarker-guided patient selection may help identify patients with sepsis who could benefit from endotoxin-targeted therapy, although confirmatory evidence is still needed.

Does High PCT Warrant Longer Therapy?

In a planned BALANCE analysis, elevated day 7 procalcitonin was associated with higher mortality, but the small subgroup analysis found no evidence that extending antibiotics from 7 to 14 days improved outcomes.

Low IMA Ligation Did Not Significantly Reduce Leaks

A randomized trial found similar short-term morbidity and 12-month functional outcomes with both approaches, while highlighting the need to balance perfusion with a tension-free anastomosis.